We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Digital Cell Morphology Platform May Replace Microscopes

By LabMedica International staff writers
Posted on 15 Jun 2022
Print article
Image: Scopio`s suite of digital full-field imaging and AI-powered decision support platforms (Photo courtesy of Scopio Labs)
Image: Scopio`s suite of digital full-field imaging and AI-powered decision support platforms (Photo courtesy of Scopio Labs)

With the increasing worldwide prevalence of hematological disorders and malignancies, the accuracy and timeliness of Peripheral Blood Smear (PBS) results are critically important for early diagnosis and effective treatment initiation. The PBS review is a powerful diagnostic tool that provides rapid, reliable access to information about a variety of disorders such as blood related cancers, anemia, infections, and allergies. The majority of these tests are performed manually, but now a disruptive PBS morphology solution completely eliminates the need for additional manual microscopic examination.

Scopio Labs’ (Tel Aviv, Israel) ground-breaking X100HT device with PBS application combines high throughput capabilities with the highest resolution for hematological analysis, catering to major medical facilities and labs across the world. In order to overcome the problem of critical shortage of medical laboratory professionals, Scopio delivers end to end digital transformation of the lab process for Full-Field PBS review of white blood cells, red blood cells, and platelet estimation. The results of every assessment (including images, annotations and flagged abnormalities) are automatically documented in a standardized digital report and seamlessly shared across the continuum of care.

In manual microscopy, users must choose between either a large field of view or high resolution. Scopio's devices eliminate that tradeoff completely, capturing large scan areas at 100X magnification. Holding 30 slides and processing up to 40 samples an hour, Scopio's X100HT can meet the high throughput requirements of large hospitals and labs, while fully supporting remote review capabilities, enabling a new subfield of telehematology. Hospital and lab networks can now operate seamlessly across multiple facilities of all sizes, with workload balancing, remote consultations, addressing personnel shortages and more. Scopio Labs has received U.S. FDA 510(k) clearance for its X100HT device with PBS Application, marking the company's second FDA clearance and broadening its suite of fully digital platforms to cater to all lab sizes and networks.

"We're excited to expand our suite of fully digital AI-powered diagnostic platforms to accelerate PBS analysis, improve consistency of results, and reduce review time," said Erez Naaman, CTO and Co-Founder of Scopio Labs. "At Scopio, we are determined to usher in the digital revolution to laboratory medicine. Our devices offer complete remote capabilities for real-time diagnosis and treatment decisions, allowing experts to review, collaborate, and consult from anywhere, and at any time, using our AI-powered applications."

Related Links:
Scopio Labs 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
Semi-Automatic Coagulation Analyzer
Clot SP
Reusable Readers
Lumos Reusable Readers

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.